Varsha Chandnani
-
Zydus, Sun Pharma, Dr Reddy's In Focus: US Cancer Drug Shortage Puts India's Pharma Stocks In Focus
According to media reports, the regulator has communicated through the Indian Drug Manufacturers' Association (IDMA) to identify companies that can immediately supply ifosfamide injection, a generic chemotherapy drug used in the treatment of several cancers, including testicular, bladder and lung cancer.
-
Cipla Share Price Gains 4% As Citi Maintains Bullish Stance For 90-Day Momentum: Check Target Price
Cipla share price opened at Rs 1,372 against a previous close of Rs 1,351.80 and extended gains by over 4% to hit an intraday high of Rs 1,409 apiece so far on the NSE.
-
US FDA Approval For Zaynich Puts Wockhardt's Innovation Bet To The Test
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.
-
Boost For Premier, Waaree Energies? Govt Says No To Blanket ALMM List II Extension — Here's What It Means
Developers had pushed back hard, citing fears of a domestic solar cell shortage, higher procurement costs and execution delays.
-
Gland Pharma Stock Rallies 13% In Trade Today — Here's Why
The stellar numbers for Gland Pharma were largely driven by a combination of factors, including strong US traction led by new launches.
-
Cohance Lifesciences Shares In Focus: Here's Why The Former Cipla Top Boss Is A Strategic Fit
Vohra's track record at Cipla makes him a strategic fit for Cohance, which is itself navigating a similar transition, from volume manufacturing toward value-based partnerships with innovator and specialty pharma clients.
-
IEX Shares Plunge After CERC Draft Rules Proposes Market Coupling
Currently, IEX acts as India's leading platform for spot electricity price discovery.
-
Fertiliser Stocks In Focus: Double Whammy for Indian Firms As China Ban Meets Iran War Disruption
China's move to curb exports of sulphuric acid—particularly the by-product from copper and zinc smelting—signals a shift toward domestic prioritisation ahead of its peak crop planting season.
-
Acutaas Chemicals: The One Stock Winning Bear Market With 'Battery Blood'
Acutaas shares have soared 85% over the last six months. The company is finding massive market success by pivoting to electric vehicle battery solvents.
-
Nifty Q3 Scorecard: SBI, TechM Power Ahead As Reliance, Tata Motors PV Slip
Among the standout performers, State Bank of India led the charts with its highest-ever quarterly profit, buoyed by a sharp rise in non-interest income.
-
Beaten Down, Not Out: Top Five Stocks That Made A December Comeback
These heavy underperformers between January and November posted notable gains in December.
-
Nifty Pharma Underperforms In 2025, Highlighting Stock-Picker's Market
With most big names failing to impress, the year turned into a classic stock-picker’s game, proof that even in a dull market, the right pills can still cure portfolios.
-
Pharma Q2FY26 Preview: Sector Faces a Transition Quarter as gRevlimid Declines and GST Impact Weigh on Growth
Lower US sales of gRevlimid are a major drag for Dr. Reddy’s, Zydus, Aurobindo, and Cipla.
-
Deals, Drugs, And Disruption: Glenmark, Lupin, IPCA Labs And Others Lead India's Pharma Opportunity Boom
The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential significant growth opportunities in oncology, biosimilars, and diabetes care.
-
Revised US Biosecure Act Could Unlock Opportunities For Indian Pharma Companies
As US drug makers reduce dependence on Chinese players, Indian CDMOs are poised to capture new opportunities.
